nivolumab,ipilimumab,relatlimab
bms
['caveat', ' ipi ', 'nivo']
based on all these caveats, we argued with in that we still don't know if ipi nivo is truly better than nivo (or other anti-pd1) in first line : 3/7 
Medicine, Oncology (sarcoma, H&N, CUP), Research = EBM, Epi, Policy #metaresearch @Hopitaux_unige (Geneva, CH), @vkprasadlab (UCSF). No COI. Views mine.